Start with a free account for 3 free CME credits. Already a subscriber? Sign in.

Atherosclerotic Cardiovascular Disease (ASCVD) Risk Management, Part 2

Spencer Blackman, MD and Rob Orman, MD
00:00
09:32
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

Part 2 of our conversation with Spencer Blackman on his group’s approach to ASCVD risk management including: specific cases, the role of niacin, and shared decision making.

 

To view chapter written summaries, you need to subscribe.

Sign up today for full access to all episodes.

David F. -

I'd be interested to hear what other physicians/experts in the field are doing with patients who were started on lipid lowering therapy prior to 2013 ACC/AHA guidelines based purely on their LDL/HDL levels and not on risk. Is there a movement to take patients off statins who would otherwise be a low or moderate risk?
Thanks

Heidi J., MD -

Hi David -
I have definitely been taking my low to moderate risk patients off the statins I put them on years ago. While the pendulum will likely swing again, I'm a fan of the current more rational statin-use trend. What have you been doing?

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.
Creme de la Thyroid Full episode audio for MD edition 180:16 min - 85 MB - M4AHippo Primary Care RAP July 2016 Summary 957 KB - PDF